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Abstract
Background: Evidence suggests that the hormonal milieu of pregnancy is an important determinant of subsequent
cancer and other chronic diseases in both the mother and the offspring. Many of the existing maternity and birth
cohorts include specimens drawn only once during pregnancy. How well a single blood specimen collected during
a pregnancy characterizes exposure to these hormones throughout gestation, and also in subsequent pregnancies,
is not well understood.
Methods: We used serial serum samples from 71 pregnant women (25 primiparous, 25 multiparous, and 21 with
two consecutive pregnancies) with natural, complication-free pregnancies and a healthy offspring at term who
participated in a population-based screening trial for congenital infections in Finland between January 1st, 1988
and June 30, 1989 and provided a blood sample in each trimester.
Results: Hormone levels were more strongly correlated between consecutive trimesters of a pregnancy than
between the 1st and 3rd trimester (e.g., estradiol, rT1 vs. T2 = 0.51 and rT2 vs. T3 = 0.60, p < 0.01; rT1 vs. T3 = 0.32, p < 0.
05). Concentrations of sRANKL remained stable throughout gestation, whereas estradiol, estrone, progesterone,
testosterone, prolactin, and osteoprotegerin increased throughout pregnancy. First trimester hormone
concentrations explained less of the variation in the third trimester on their own than second trimester hormone
levels (e.g. estradiol R2T1 = 16 % and R
2
T2 = 42 %). Addition of maternal (e.g., smoking) and/or child characteristics (e.g.,
sex) improved the accuracy of the 3rd trimester estimates for some of the hormones.
Conclusions: One hormone measurement in early pregnancy, in conjunction with maternal and fetal
characteristics, permits estimation of 3rd trimester hormone concentrations. Therefore, single hormone
measurements available from maternity cohorts are suitable to quantify hormone exposure during pregnancy. To
our knowledge, we provide the first data on correlations between hormone concentrations both across trimesters
of a single pregnancy, as well as between two subsequent pregnancies.
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Background
The hormonal milieu of pregnancy may be an important
determinant of subsequent cancer and other chronic dis-
eases both in the mother and the offspring [1, 2].
Depending on the outcome of interest, hormone con-
centrations measured at different periods during preg-
nancy may be of relevance. For instance, hormones
measured in early pregnancy, during which fetal organo-
genesis takes place, may be important when neurodeve-
lopmental conditions in the offspring are of interest,
whereas hormone concentrations during late pregnancy
may be relevant in relation to maternal risk of breast
and ovarian cancers, given evidence that complete preg-
nancies are associated with these malignancies [3, 4].
Established biorepositories in Northern Europe (e.g.,
Finland) store sera collected during early pregnancy
(predominantly in weeks 8 to 14) for screening of sys-
temic infections such as HIV, hepatitis, and/or rubella.
Worldwide, maternity and birth cohorts have been
established to study associations between pregnancy and
early-life exposures with health and disease outcomes in
the mother and/or the offspring. Many of the existing
cohorts include specimens drawn once during the first
half of pregnancy [5–9], with few collections obtaining a
blood sample later in pregnancy [10, 11]. Furthermore,
only few studies obtained blood in consecutive trimes-
ters from sizeable cohorts of pregnant women [12–14].
For many outcomes (e.g., chronic diseases in the off-
spring in adulthood), a large study population is neces-
sary as cohort members must be followed as long as de-
cades to accumulate a sufficient number of cases for an
investigation.
Whether a hormonal measurement from a single
blood specimen collected early during a complication-
free pregnancy is representative of exposure throughout
gestation, or exposure in a subsequent pregnancy, is not
established. From a research perspective, this knowledge
could help optimize the use of existing maternity co-
horts in which only specimens drawn once during the
first half of pregnancy are available.
Therefore, the aim of our study was to explore the
correlations between hormone concentrations measured
in serum during the 1st, 2nd, and 3rd trimester of (1) a
single uncomplicated pregnancy, (2) two subsequent un-
complicated pregnancies, and (3) to calculate how well
1st and/or 2nd trimester hormone levels estimate con-
centrations during 3rd trimester in an uncomplicated
pregnancy. We measured sex steroids (estradiol, estrone,
progesterone, and testosterone) and prolactin that are
implicated in the development of maternal breast and
ovarian cancer [1] and two new biomarkers (osteopro-
tegerin [OPG] and soluble receptor activator of nuclear
factor kappaB ligand [sRANKL]) that have not yet been
studied in detail.
Methods
We used serum samples from pregnant women collected
in a population-based screening trial for congenital in-
fections between January 1st, 1988 and June 30, 1989 in
the 76 maternity centers in the metropolitan Helsinki
(Finland) area. All pregnant women aged 15–45 years (n
= 18,616) were invited to donate a blood sample during
the 1st, 2nd, and 3rd trimesters of a pregnancy [14].
Among the 16,793 participants (90 %) who donated
three serum samples we first selected women with a
singleton, healthy offspring at term resulting from a nat-
ural, uncomplicated pregnancy. Women with an uncom-
plicated pregnancy were defined as women not being
diagnosed with pre-eclampsia or hypertension during
pregnancy and not being hospitalized due to threatening
premature delivery or bleeding. In a second step, we ran-
domly selected 25 women giving birth to their first child
(primipara) and 25 women giving birth to their second
child (multipara), aged 20–34 years and whose blood
samples were obtained at weeks 10–12 (T1), weeks 20–
22 (T2), and weeks 35–37 (T3) of one pregnancy. Add-
itionally, 21 women with two consecutive singleton preg-
nancies during the study period were included. These
women donated samples for both pregnancies in gesta-
tional weeks 8–14, 18–24, and 33–38. All blood samples
were processed using a standardized protocol and stored
at −20 °C [14].
Characteristics related to pregnancy (e.g., smoking
during early pregnancy, pregnancy length, parity) and to
the newborn (e.g., gender, birth weight and birth length)
were obtained through linkages from the Finnish birth
registry.
The study was approved by the ethical committees of
the National Institute for Health and Welfare, Finland,
University of Umeå, Sweden, and University of Heidel-
berg, Germany.
Laboratory analyses
All hormonal analyses were performed at the Clinical
Chemistry Laboratory of Umeå University Hospital,
Umeå, Sweden. Serum specimens from each woman
were assayed in the same laboratory run. In addition to
routine laboratory quality controls, a pool of serum was
created at the beginning of the study and two aliquots,
undistinguishable from the study samples were inserted
in each laboratory run. All reported intra- and inter-
assay coefficients of variation (CV) are based on the
blinded pool quality controls.
Serum concentrations of sex steroids were quantified
by high-performance liquid chromatography tandem
mass spectrometry (HPLC-MS) on an Applied Biosys-
tems API4000 triple stage quadrupole mass spectrom-
eter. Serum prolactin (PRL) concentrations were
measured by immunoassay (Elecsys Prolactin II, Roche,
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Mannheim, Germany). The determination of serum os-
teoprotegerin (OPG) concentrations was performed by
enzyme-linked immunosorbent assay (TNFRSF11B (Hu-
man) ELISA Kit, Abnova). Serum soluble RANK ligand
(sRANKL) concentrations were determined by immuno-
assay (ampli-sRANKL, Biomedica, Vienna, Austria).
Intra- and inter-assay CVs were <18 % for all hor-
mones with the exception of testosterone. The intra-
assay CV for testosterone was 12 %, whereas the inter-
assay CV was 44 %. After removing a single batch for
testosterone, the inter-assay CV decreased to 12 %.
Out of 150 samples, sRANKL was below the detection
limit in 21 samples, OPG was below the detection limit
in one sample, and prolactin was below the detection
limit in four samples.
Sex steroid hormones were measured in all samples,
whereas PRL, OPG, and sRANKL were measured only
in samples from women who gave birth once during the
study period.
Statistical analyses
Women with one pregnancy were analyzed separately
from those with two pregnancies.
Spearman's rank correlation coefficient was used to as-
sess the correlations between the investigated hormones
at the same point in time as well as between-trimester
correlations for each hormone, and to measure the cor-
relation of hormone concentrations between two con-
secutive pregnancies in the same woman. To test for
differences between the correlation coefficients in the
primiparous and multiparous women each correlation
coefficient was converted into a z-score using Fisher's
r-to-z transformation. The z-scores were then compared
taking into account the sample sizes employed to obtain
each coefficient [15]. We considered adjustment for
multiple comparison using the Bonferroni method (pBonf
< 0.05/145 = 0.0003) as a secondary analysis.
We calculated median percentage changes in maternal
hormone concentrations from the 1st to 3rd trimester
and used the Kruskal Wallis test (pKW) to test the differ-
ences in hormone concentrations between the trimes-
ters. The Mann–Whitney-U test (pMW) was used to
assess whether hormone concentrations in the three tri-
mesters were significantly different by parity (primipara
vs. multipara), smoking status at first blood draw
(current vs. no), and fetal sex (male vs. female).
The percentage changes in the 3rd trimester hormone
concentrations were estimated per 1 % increase in hor-
mone levels measured in the 1st and/or 2nd trimester,
adjusted for gestational age. Maternal and newborn
characteristics were added to these models one at a time
to assess their individual contribution to 3rd trimester
hormone concentrations.
We used the Wilcoxon signed rank sum test (pWS) to
compare differences in hormone concentrations between
trimesters of the two consecutive pregnancies.
For the study population of women with one full-term
pregnancy, we conducted sensitivity analyses limited to
women who were pregnant for the first (primigravid;
n = 19) or second time (multigravid; n = 19) to assess
whether observed differences between primiparous and
multiparous women were due to gravidity or parity.
Analyses on sRANKL were repeated replacing the miss-
ing values with the lower limit of detection of the assay
(0.02 pmol/L).
All statistical tests were two-sided and considered sig-
nificant at p < 0.05. Statistical analyses were performed
with the Statistical Analyses System (SAS), version 9.3
(SAS Institute, Inc., Cary, North Carolina).
Results
The baseline characteristics of all study participants are
presented in Table 1. Maternal and child characteristics
were similar between primiparous women, multiparous
women, and women participating with two consecutive
pregnancies. Overall, the majority of study participants
did not smoke during pregnancy (n = 52; 73 %) and
more pregnancies ended in the delivery of a boy (n = 51;
55 %) than a girl (n = 41; 45 %).
Associations across trimesters of one pregnancy
Hormones of placental origin (estradiol, estrone, and
progesterone) were highly correlated with each other
(r > 0.72, p < 0.0001) and with PRL (r > 0.68, p < 0.0001;
data not shown). More modest correlations were ob-
served for OPG with PRL (r = 0.51), estrone (r = 0.52),
estradiol (r = 0.59), and progesterone (r = 0.61; p for
all <0.0001). Testosterone and progesterone were posi-
tively correlated (r = 0.34, p < 0.0001), whereas testoster-
one and sRANKL were negatively correlated (r = −0.30,
p = 0.001). Gestational age was highly correlated with
OPG, PRL, estrone, progesterone, and estradiol (r = 0.63
(OPG) to r = 0.89 (estradiol); p < 0.0001). Weak, border-
line significant correlations in the 2nd and 3rd trimesters
were observed for OPG with child length (rT2 = 0.33,
rT3 = 0.28; p ≤ 0.05) and child weight (rT2 = 0.24, rT3 =
0.26; pT3 ≤ 0.10). Irrespective of trimester, sRANKL was
not significantly correlated with child length (e.g., rT3 =
0.20, pT3 = 0.20) or child weight (e.g., rT3 = 0.11, pT3 =
0.47; data not shown).
Hormone concentrations were more strongly corre-
lated between consecutive trimesters of a pregnancy
than between the 1st and 3rd trimester (e.g. estradiol,
rT1 vs. T2 = 0.51 and rT2 vs. T3 = 0.60, p < 0.01; rT1 vs. T3 =
0.32, p < 0.05; Table 2). Correlation coefficients in the
primiparous and multiparous women were significantly
different for estrone (pT1 vs. T3 = 0.01) and sRANKL
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(pT1 vs. T2 < 0.001; Table 2). Using the Bonferroni cor-
rected p-value of 0.0003 (pBonf = 0.05/145), correlation
coefficients remained significant between hormones and
with GA, as well as between the trimesters of a single
pregnancy overall and for sRANKL in primiparous and
multiparous women.
We examined median hormone concentrations across
trimesters and the median %-change from 1st to 3rd tri-
mester overall and by parity (Table 3). The 1st to the 3rd
trimester median levels increased significantly (pKW <
0.0001) 1.5-fold for OPG, 4-fold for progesterone, 6-fold
for PRL, 9-fold for estradiol, and 10-fold for estrone.
Testosterone and sRANKL concentrations did not
change significantly across pregnancy.
Progesterone and testosterone concentrations were
lower in multiparous women as compared to primipar-
ous women throughout gestation (e.g., progesterone T3
primi = 138 ng/mL, T3 multi = 107 ng/mL; pMW = 0.007;
testosterone T3 primi = 2.56 ng/mL, T3 multi = 0.71 ng/mL;
pMW = 0.0008). In contrast, concentrations of sRANKL
were slightly higher in multiparous as compared to
primiparous women, although this difference only
reached statistical significance in the first trimester (T1
primi = 0.32 pmol/L, T1 multi = 0.56 pmol/L; pMW = 0.04).
Hormone concentration trajectories for primiparous and
multiparous women are shown in Fig. 1.
Testosterone concentrations were higher throughout
gestation in women who reported smoking in early preg-
nancy relative to non-smoking women (e.g. T1 smoker =
1.69 ng/mL, T1 non-smoker = 0.89 ng/mL; pMW = 0.03).
Third trimester concentrations of estradiol were higher
in women reporting smoking in early pregnancy as
compared to non-smoking women (T3 smoker = 25.7 ng/
mL, T3 non-smoker = 18.6 ng/mL; pMW = 0.01), whereas
levels of PRL were lower (T3 smoker = 136 ng/mL, T3 non-
smoker = 221 ng/mL; pMW = 0.05). Lower PRL was ob-
served in women carrying a boy as compared to women
pregnant with a girl. However, this difference only
reached statistical significance in the first trimester (T1
boy = 23.7 ng/mL; T1 girl = 32.7 ng/mL; pMW = 0.02; T2
boy = 101.6 ng/mL; T2 girl = 147.4 ng/mL; pMW = 0.09; T3
boy = 175.3 ng/mL; T3 girl = 222.4 ng/mL; pMW = 0.38;
data not shown).
We further examined the effect of a 1 % unit increase
in 1st and/or 2nd trimester hormone concentrations on
the estimates of 3rd trimester hormone concentrations.
Hormone concentrations measured in the 1st tri-
mester accounted for 10 % (PRL) to 58 % (sRANKL)
of the variation in the 3rd trimester (basic model,
Table 4A). Women who were pregnant with their sec-
ond child had significantly lower progesterone (24 %)
but higher PRL (32 %) concentrations than primipar-
ous women. Women who smoked at study enrollment
had higher concentrations of estradiol (42 %) and tes-
tosterone (85 %), but lower PRL concentrations
(41 %) compared to non-smoking women. Models
that included all covariates and the 1st trimester hor-
mone measurement (full-model, Table 4A) accounted
for 7 % (progesterone) to 30 % (estradiol) more of
the variation than a model based solely on the 1st tri-
mester hormone level, with the exception of OPG
(0 %) and sRANKL (-2 %).
Second trimester hormone concentrations explained
36 % (OPG) to 71 % (sRANKL) of the variation in the
Table 1 Baseline characteristics; median (range), or n (%)
One pregnancy during study period Two consecutive pregnancies during study period
Characteristics Primiparous (n = 25) Multiparous (n = 25) Pregnancy 1 (n = 21) Pregnancy 2 (n = 21)
Maternal age, years 27.2 (20.6–33.5) 27.5 (20.5–33.1) 26.5 (17.8–42.7) 27.7 (18.6–44.0)
Pregnancy length, days 282 (255–296) 283 (266–292) 279 (258–294) 278 (262–291)
Parity
0 25 (100 %) 13 (62 %)
1 25 (100 %) 6 (29 %) 13 (62 %)
2 2 (9 %) 6 (29 %)
3 2 (9 %)
Child weight, kg 3.3 (2.4–4.7) 3.8 (2.8–4.6) 3.5 (2.8–4.5) 3.8 (2.9–4.3)
Child length, cm 49 (45–55) 51 (47–54) 50 (47–53) 50 (49–53)
Child sex
Boy 10 (40 %) 13 (52 %) 14 (67 %) 14 (67 %)
Girl 15 (60 %) 12 (48 %) 7 (33 %) 7 (33 %)
Maternal smoking
No 19 (76 %) 20 (91 %) 13 (62 %) 13 (65 %)
Yes 6 (24 %) 2 (9 %) 8 (38 %) 7 (35 %)
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3rd trimester on their own. Addition of maternal or
child characteristics resulted in changes similar to those
observed using 1st trimester concentrations (Table 4B),
with slightly increased adjusted R2 statistics for testoster-
one, estradiol, progesterone, and PRL (7 % for testoster-
one to 12 % for PRL).
Models that included both 1st and 2nd trimester hor-
mone concentrations but no other variables accounted
for 37 % (OPG) to 70 % (sRANKL) of the variation
observed in the 3rd trimester (Table 4C); results were
similar after addition of all maternal and newborn
characteristics.
Finally, we examined the extent to which 2nd and
3rd trimester hormone concentrations were associated
with 1st trimester concentrations: second trimester
hormone concentrations explained 25 % (estradiol
and PRL) to 73 % (sRANKL) of the variation in the
1st trimester on their own, with slightly improve-
ments after addition of maternal or child characteris-
tics (Additional file 1A). Third trimester hormone
concentrations explained <31 % (all hormones except
sRANKL) of the variation in the 1st trimester on
their own (Additional file 1B). Addition of 3rd trimes-
ter hormone concentrations to models based on 2nd
trimester hormone concentrations did not improve
adjusted R2 statistics (Additional file 1C).
Two consecutive pregnancies
Next, we compared hormone concentrations during
each trimester in women providing samples from two
consecutive pregnancies. The correlations between two
consecutive pregnancies for individual hormones by tri-
mester are presented in Table 5. First trimester proges-
terone concentrations (r = 0.47; p < 0.05) were most
strongly correlated between pregnancies, whereas for es-
tradiol and testosterone the between-pregnancy correla-
tions were strongest in the 3rd trimester (rE2 = 0.68, rT =
0.69; p < 0.01). Concentrations of estrone were well cor-
related in all trimesters (r > 0.59; p < 0.01). Using the
Bonferroni corrected p-value of 0.0003, 1st trimester es-
trone remained significantly correlated between
pregnancies.
Median changes between the two pregnancies were
low (Table 6) and showed no significant differences with
the exception of testosterone in the 3rd trimester (T3
pregnancy 1 = 1.04 ng/mL, T3 pregnancy 2 = 0.89 ng/mL; pWS
= 0.02). When comparing testosterone concentrations by
parity, primiparous women had higher 3rd trimester tes-
tosterone levels than multiparous women (T3 primi =
1.04 ng/mL, T3 multi = 0.98 ng/mL; pWS = 0.007). How-
ever, no further decrease in 3rd trimester testosterone
levels was evident when comparing multiparous women
to women with three children (T3 multi = 0.98 ng/mL, T3
3 ch = 0.94 ng/mL; pws = 0.31).
Sensitivity analyses (data not shown)
Results did not change when limiting the study popula-
tion to primi- and multi-gravid women.
The presented results for testosterone are based on all
measurements. Excluding the testosterone measure-
ments from the batch that resulted in higher inter-batch
CVs for this hormone (n = 80 samples) did not change
the direction or significance of the associations with the
exception of attenuated results for 3rd trimester levels
by parity (original: T3 primi = 2.56 ng/mL vs. T3 multi =
0.71 ng/mL, pMW < 0.01; limited: T3 primi = 2.16 ng/mL
vs. T3 multi = 0.69 ng/mL, pMW = 0.13).
Sensitivity analyses were also conducted replacing
missing sRANKL values (n = 21 samples) with the lower
detection limit of 0.02 pmol/L. This approach did not
change the direction or significance of the associations
(e.g., original: T1 primi = 0.32 pmol/L vs. T1 multi = 0.56
pmol/L, pMW = 0.04; replaced T1 primi = 0.22 pmol/L vs.
T1 multi = 0.53 pmol/L, pMW = 0.04).
Table 2 Spearman correlation coefficients adjusted for
gestational age between successive trimesters of one
pregnancy a
Overall Primiparous Multiparous
Trimester 1st 2nd 1st 2nd 1st 2nd
Estradiol
2nd 0.509 ** 0.518 *** 0.519 ***
3rd 0.319 *** 0.597 * 0.376 0.629 ** 0.121 0.519 ***
Estrone
2nd 0.519 ** 0.742 * 0.307
3rd 0.293 0.609 * 0.592 ** 0.707 ** −0.107 0.521 ***
Progesterone
2nd 0.629 * 0.306 0.719 *
3rd 0.394 ** 0.643 * 0.321 0.569 *** 0.323 0.672 **
Testosterone
2nd 0.674 * 0.789 * 0.511 ***
3rd 0.508 ** 0.765 * 0.614 ** 0.850 * 0.240 0.551 **
Prolactin
2nd 0.575 * 0.739 * 0.464 ***
3rd 0.327 *** 0.686 * 0.675 ** 0.660 ** 0.315 0.661 **
OPG
2nd 0.538 * 0.631 ** 0.406
3rd 0.497 ** 0.779 * 0.574 *** 0.643 ** 0.441 *** 0.827 *
sRANKL
2nd 0.774 * 0.968 * 0.427
3rd 0.729 * 0.818 * 0.806 * 0.878 * 0.528 *** 0.808 *
Significant p-values are indicated as * < 0.0003 (Bonferroni corrected p-value),
** < 0.01, *** < 0.05
a Correlation coefficients in bold indicate a significant difference (p < 0.05)
comparing primiparous vs. multiparous women
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Discussion
To our knowledge, we provide the first observational
data on correlations between hormone concentrations
both across trimesters of a single pregnancy, as well as
between two subsequent pregnancies. Our data show
that third trimester hormone concentrations can be esti-
mated from concentrations measured in the 1st or 2nd
trimester, and that including maternal and fetal covari-
ates, most notably parity, smoking, and fetal sex im-
proved the estimates.
Sex steroids
During the first 9 weeks of pregnancy the corpus luteum
and, to a lesser extent, the maternal ovary and the
Table 3 Median hormone concentrations (10–90th percentiles) overall and by parity a
All women
(n = 50)
Primiparous
(n = 25)
Multiparous
(n = 25)
pMW
c
Estradiol (ng/mL)
1st trimester 2.18 (1.16–3.59) 2.11 (1.19–4.00) 2.42 (1.12–3.12) 0.92
2nd trimester 9.71 (5.33–15.1) 10.3 (5.20–14.8) 9.45 (5.46–15.3) 0.64
3rd trimester 20.4 (12.8–32.9) 22.3 (13.6–35.6) 19.5 (12.8–31.5) 0.71
Median %-change b 876 % 858 % 889 %
Estrone (ng/mL)
1st trimester 0.93 (0.41–1.72) 0.71 (0.35–2.07) 1.11 (0.48–1.60) 0.14
2nd trimester 4.28 (1.99–8.54) 3.96 (1.64–8.84) 4.56 (2.77–6.88) 0.85
3rd trimester 11.5 (3.70–18.9) 10.4 (3.65–21.3) 11.7 (3.77–17.8) 0.92
Median %-change b 976 % 919 % 1053 %
Progesterone (ng/mL)
1st trimester 25.6 (16.6–40.7) 27.3 (20.0–42.2) 23.0 (13.5–37.8) 0.03
2nd trimester 48.1 (31.6–78.5) 53.8 (37.8–85.2) 42.1 (28.7–71.3) 0.03
3rd trimester 130 (72.6–200) 138 (105–215) 107 (60.2–163) 0.007
Median %-change b 411 % 422 % 396 %
Testosterone (ng/mL)
1st trimester 0.96 (0.42–1.98) 1.34 (0.78–2.15) 0.66 (0.36–1.11) <0.0001
2nd trimester 1.19 (0.55–3.35) 1.98 (1.05–3.96) 0.73 (0.44–1.43) <0.0001
3rd trimester 1.32 (0.50–4.07) 2.56 (0.54–6.06) 0.71 (0.50–2.41) 0.0008
Median %-change b 61 % 74 % 38 %
Prolactin (ng/mL)
1st trimester 28.8 (16.3–57.6) 32.6 (19.8–63.3) 27.6 (10.6–47.0) 0.10
2nd trimester 126 (54.9–206) 105 (49.0–181) 139 (72–206) 0.32
3rd trimester 216 (124–318) 177 (115–258) 225 (133–320) 0.12
Median %-change b 570 % 449 % 795 %
OPG (pmol/L)
1st trimester 3.79 (2.63–5.90) 3.45 (2.71–5.61) 3.93 (2.37–5.99) 0.21
2nd trimester 5.26 (3.10–7.91) 4.96 (3.28–7.15) 6.01 (3.10–9.01) 0.17
3rd trimester 9.74 (4.44–17.5) 8.18 (4.09–20.3) 10.5 (5.59–16.4) 0.12
Median %-change b 143 % 112 % 162 %
sRANKL (pmol/L)
1st trimester 0.43 (0.10–0.81) 0.32 (0.06–0.92) 0.56 (0.31–0.74) 0.04
2nd trimester 0.43 (0.10–0.91) 0.31 (0.06–1.05) 0.51 (0.27–0.81) 0.26
3rd trimester 0.43 (0.20–0.82) 0.41 (0.14–0.95) 0.43 (0.30–0.72) 0.35
Median %-change b 8 % 30 % −14 %
a Conversion from ng/ml to nmol/l (SI units): estradiol*3.671, estrone*3.699, progesterone*3.18, testosterone*3.467, and prolactin*0.04348
b Median %-change between 1st and 3rd trimester
c p-value obtained from the Mann–Whitney-U test comparing primi- and multiparous women
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adrenal cortex, contribute to circulating concentrations
of maternal estradiol, estrone, and progesterone. After
this period, the placenta becomes the predominant
source of maternal steroids [16]. The substantial increase
in maternal serum concentrations of estradiol, estrone,
and progesterone throughout pregnancy is well estab-
lished and was also evident in our study [16, 17]. The
weaker and gradual increase in testosterone concentra-
tion across gestation has also been reported in prior lon-
gitudinal studies [17, 18].
Estradiol concentrations were correlated in two suc-
cessive pregnancies in our investigation, with stronger
coefficients in the 3rd (r = 0.68) as compared to the 1st
(r = 0.47) trimester. A previous study based on 34
women with uncomplicated first and second full-term
pregnancies reported a strong correlation (r = 0.78) be-
tween early estradiol levels in the consecutive pregnan-
cies [19].
We observed a non-significant suggestion of lower es-
tradiol concentrations throughout pregnancy in multip-
arous women. This is consistent with previous studies
reporting lower first and second trimester estradiol
levels in multiparous as compared to primiparous
women [20–24]. The decreased concentrations of estra-
diol in multiparous women are hypothesized to be a re-
sult of increased pregnancy-induced 16α-hydroxylase
activity in the maternal liver during earlier pregnancies
leading to increased metabolism of estradiol and thus
lower circulating estradiol in subsequent pregnancies
[25]. We observed significantly lower progesterone and
testosterone concentrations in multiparous as compared
to primiparous women; this was also reported in prior
studies on early pregnancy hormones [21–24].
Women who smoked during pregnancy had higher
3rd trimester estradiol levels than non-smoking women.
Prior studies based on 1st or 2nd trimester measure-
ments reported no association of estradiol concentra-
tions with smoking [21, 22, 24]. In agreement with our
results, higher testosterone levels in smoking women
were also observed in one [22] of two studies [24].
We observed no differences in hormone concentra-
tions between women pregnant with a boy or a girl.
Fig 1 Trajectories of hormone concentrations in 25 primiparous and 25 multiparous women. Hormones are log2-transformed to fit in one graph
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Prior studies are inconsistent, with some reporting an
increase in early pregnancy estradiol and testosterone
concentrations in women pregnant with a girl [22, 23],
and others observing no differences by fetal gender [21,
26]. A decrease in pregnancy progesterone levels in
women carrying a female fetus was observed in one
study that collected blood at gestational weeks 16 and
27 [21], but not in studies conducted in gestational
weeks 6–20 [22, 23, 27].
Prolactin
Prolactin is produced by the pituitary gland in a pulsatile
fashion and plays essential roles in mammary develop-
ment and lactation, as well as reproduction [28]. Though
the decidua or the fetus cannot be ruled out as a poten-
tial source of PRL during pregnancy, it is believed that
the maternal pituitary is the main source of PRL secre-
tion in pregnant women [29].
We observed an increase in PRL levels with progres-
sing pregnancy; this is consistent with prior longitudinal
studies [17, 30] and a cross-sectional study [29]. The in-
crease in PRL concentration is believed to result from
the stimulatory effect of estradiol, and to a lesser extent
progesterone, on the pituitary gland [29].
Contrary to previous reports, we did not observe lower
prolactin levels in multiparous as compared to primipar-
ous women [20, 30]. Estrogens are hypothesized to
stimulate the enlargement of the pituitary gland during
pregnancy resulting in increased PRL concentrations,
Table 4 Percentage changes [95 % confidence intervals] in 3rd trimester hormone concentrations given 1st and 2nd trimester
concentrations and maternal and newborn characteristics a
Estradiol Estrone Progesterone Testosterone Prolactin OPG sRANKL
A)
1st trimester hormone only 26 [7, 50] 31 [7, 62] 34 [10, 63] 71 [36, 115] 16 [3, 31] 33 [13, 57] 52 [35, 71]
Adjusted R2 - basic model 16 % 10 % 13 % 31 % 10 % 18 % 58 %
1st trimester hormone
Age at blood draw −2 [−5, 1] −1 [−7, 4] 0 [−3, 3] −2 [−8, 5] 1 [−2, 4] −2 [−5, 2] −3 [−7, 1]
Smoking 42 [11, 82] 33 [−20, 113] 14 [−13, 45] 85 [2, 236] −41 [−82, −9] −12 [−61, 29] −27 [−103, 25]
Parity −5 [−28, 16] −4 [−49, 38] −24 [−50, −3] −57 [−158, 4] 32 [9, 60] 21 [−6, 55] −18 [−58, 14]
Child sex 27 [4, 54] 11 [−30, 59] 16 [−4, 40] 11 [−39, 71] 1 [−23, 27] 21 [−7, 56] 0 [−34, 34]
Birth length [per 5 cm] −13 [−40, 9] −39 [−102, 5] −5 [−29, 17] 12 [−41, 76] 21 [−2, 51] 32 [0, 72] 12 [−23, 56]
Birth weight [per 100 g] −1 [−2, 1] −1 [−5, 2] −1 [−2, 1] 0 [−4, 5] 2 [0, 4] 2 [0, 5] 1 [−2, 4]
Adjusted R2 - full model 46 % 23 % 20 % 39 % 22 % 18 % 56 %
B)
2nd trimester hormone only 57 [35, 83] 76 [45, 114] 57 [36, 82] 103 [72, 140] 44 [29, 60] 64 [36, 98] 61 [45, 78]
Adjusted R2 - basic model 42 % 40 % 45 % 63 % 55 % 36 % 71 %
2nd trimester hormone
Age at blood draw −1 [−3, 2] 0 [−4, 5] 0 [−2, 2] 1 [−4, 6] −1 [−3, 1] −3 [−7, 0] −3 [−6, 1]
Smoking 27 [2, 57] 21 [−22, 79] 20 [0, 44] 59 [1, 151] −26 [−50, −5] −1 [−41, 37] −21 [−83, 25]
Parity −2 [−21, 16] 2 [−30, 37] −17 [−36, 0] −8 [−63, 40] 16 [1, 34] 12 [−12, 42] −8 [−39, 19]
Child sex 8 [−9, 27] −8 [−44, 24] 4 [−12, 22] −10 [−52, 27] 2 [−15, 18] 7 [−18, 35] −4 [−34, 23]
Birth length [per 5 cm] −10 [−31, 9] −20 [−63, 14] −11 [−31, 6] 11 [−26, 57] 18 [1, 38] 14 [−14, 48] 24 [−5, 62]
Birth weight [per 100 g] −1 [−3, 1] −1 [−4, 2] −1 [−2, 0] 0 [−3, 3] 1 [0, 2] 1 [−1, 4] 2 [−1, 4]
Adjusted R2 - full model 51 % 39 % 54 % 70 % 67 % 31 % 70 %
C)
1st & 2nd trimester hormones
Adjusted R2 - basic model 45 % 38 % 45 % 61 % 57 % 37 % 70 %
Adjusted R2 - full model 55 % 38 % 52 % 67 % 69 % 32 % 69 %
a All models include 1st or 2nd trimester hormone concentration and the respective gestational age
Table 5 Spearman correlation coefficients adjusted for
gestational age in the trimesters between two successive
pregnancies
Trimester Estradiol Estrone Progesterone Testosterone
1 0.467 0.761 * 0.469 *** 0.495 ***
2 0.353 0.592 ** −0.214 0.526 ***
3 0.683 ** 0.717 ** 0.371 0.694 **
Significant p-values are indicated as * < 0.0003 (Bonferroni corrected p-value),
** < 0.01, *** < 0.05
Schock et al. BMC Pregnancy and Childbirth  (2016) 16:146 Page 8 of 11
which parallel the increase in estrogens [29, 31]. In our
study, the lack of an association between parity and PRL
may be explained by the similar estradiol concentrations
irrespective of parity. Two prior studies showing a de-
crease in PRL also observed decreased estradiol concen-
trations in multiparous women [20, 24].
Past studies reported lower early pregnancy PRL in
women smoking during pregnancy as compared to non-
smoking women [24, 30]. We observed a non-significant
suggestion of lower PRL concentrations in smoking
women in the 1st and 2nd trimester and significantly
lower PRL levels in the 3rd trimester. Given that nicotine
exposure induces dopamine release, which inhibits PRL
secretion, smoking may cause reduced PRL levels [32].
We further observed significantly lower first trimester
PRL levels in women pregnant with a boy as compared
to women pregnant with a girl, whereas the lower levels
in the 2nd or 3rd trimester were not significantly differ-
ent. Prior studies investigating gender-related differences
are inconclusive and reported lower levels in women
carrying a girl (gestational weeks 16, 27, 34, or 36) [30,
33] or no association with fetal sex (gestational weeks
6–20, 28–32, 33–36, or 40) [34, 35]. A recent longitu-
dinal study showed decreased PRL concentrations in
women pregnant with a girl in gestation weeks 9–17 and
increased concentrations at delivery [27]. A plausible ex-
planation for our findings is difficult to formulate as no
consistent pattern is evident from available data. It is
likely that the observed changes are not gender-related
but due to other factors influencing PRL levels, such as
stress or fasting status. However, data on these factors
were not available for our study.
OPG and sRANKL
OPG and sRANKL are members of the tumor necrosis
factor family and are involved in the regulation of bone
resorption and bone mass [36].
The observed increase in OPG serum concentrations
during pregnancy in our data has been reported in other
longitudinal [37–39] and cross-sectional studies [40].
The main source of maternal serum OPG during preg-
nancy is unclear, however the placenta and breast tissue
express high amounts of OPG [37–39]. Concentrations
of OPG did not vary with neonatal gender or parity in
our study, consistent with a prior report [40].
We did not see any change in sRANKL concentrations
during pregnancy in our data. To our knowledge, the only
other study on sRANKL in pregnancy observed lower con-
centrations in late pregnancy as compared to pre-
conception levels (mean at week 36 = 0.77 vs. mean before
pregnancy = 1.03; p = 0.03) [38]. We observed higher first
trimester sRANKL concentrations in multiparous women
than in primiparous women; to our knowledge this has not
been previously reported.
Birth length, and to a lesser extent birth weight,
were weakly correlated with OPG and sRANKL. To
our knowledge, the only other study available to date
observed positive correlations of child’s length and
weight with sRANKL, but not with OPG concentra-
tions at birth [41].
Table 6 Median hormone concentrations (10th-90th percentiles) and median change by trimester in 21 consecutive pregnancies a
Pregnancy 1 Pregnancy 2 Median change pWS
b
Estradiol (ng/mL)
1st trimester 2.32 (1.27–3.76) 1.98 (1.11–3.58) −0.3 (−1.3; −1.3) 0.10
2nd trimester 9.00 (5.91–13.3) 7.96 (5.21–13.2) −0.3 (−0.9; 1.3) 0.18
3rd trimester 22.6 (16.2–34.2) 20.0 (14.2–32.0) −0.2 (−0.9; 0.5) 0.07
Estrone (ng/mL)
1st trimester 0.73 (0.42–1.60) 0.73 (0.28–1.50) −0.2 (−1.1; 0.5) 0.11
2nd trimester 4.19 (2.03–6.76) 3.90 (1.67–8.17) −0.2 (−1.0; 0.4) 0.10
3rd trimester 8.00 (4.34–17.1) 7.80 (3.32–12.2) −0.3 (−0.6; 0.2) 0.08
Progesterone (ng/mL)
1st trimester 30.6 (22.1–47.4) 31.2 (22.9–45.0) 0 (−0.5; 0.6) 0.65
2nd trimester 56.9 (39.3–85.3) 62.3 (40.4–78.7) −0.1 (−0.8; 1.0) 0.96
3rd trimester 161 (127–207) 165 (123–225) 0.1 (−0.7; 0.5) 0.55
Testosterone (ng/mL)
1st trimester 0.84 (0.52–1.38) 0.78 (0.46–1.43) 0 (−1.2; 0.5) 0.31
2nd trimester 1.10 (0.68–1.67) 1.02 (0.55–1.50) −0.2 (−0.9; 0.6) 0.09
3rd trimester 1.04 (0.60–2.88) 0.89 (0.60–1.45) −0.4 (−1.0; 0.2) 0.002
a Conversion from ng/ml to nmol/l (SI units): estradiol*3.671, estrone*3.699, progesterone*3.18, testosterone*3.467, and prolactin*0.04348
b p-value obtained from the Wilcoxon signed rank sum test
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Our study has a number of strengths: 1) we specified
2-week ranges in each trimester for sample collection to
account for the changing hormone concentrations dur-
ing pregnancy; 2) with the equal number of primiparous
and multiparous women, we were able to investigate
hormone variations by parity; and 3) we focused on un-
complicated pregnancies with a healthy singleton off-
spring, as pregnancy-related complications (e.g. pre-
eclampsia) can cause changes in the hormonal milieu.
One limitation is that sRANKL could not be quantified
in 21 samples (14 %), as values were below the limit of de-
tection. This might be because the majority of RANKL is
cell bound and therefore not detectable in the circulation
[42]. However, sRANKL concentrations did not change
during pregnancy and results based on the original values
were almost identical when compared to those replacing
the missing measurements by 0.02 pmol/L; the lower limit
of detection of the assay. Another limitation is that smok-
ing status was assessed during the first trimester only. As
more than 60 % of women who smoke in the first trimes-
ter are reported to continue throughout pregnancy, [43,
44] the observed changes in estradiol, testosterone, and
PRL levels are thus likely to represent concentrations in
current smokers. Furthermore, we cannot rule out that
some of our findings are due to chance as the sample size
in some of the subgroup analyses was limited. Finally,
while results of this study are informative for research
purposes, they are not of clinical significance.
Conclusions
Our observational study shows that hormone concentra-
tions measured in the 1st, 2nd, or 3rd trimester are cor-
related, as are hormone concentrations between
pregnancies. Furthermore, to some extent it is possible
to estimate selected 3rd trimester hormone concentra-
tions based on one hormone measurement drawn in
early gestation and pregnancy characteristics, whereas it
appears to be less reliable to estimate early pregnancy
concentrations using measurements from late preg-
nancy. As it is hypothesized that pregnancy is related to
disease later in the mother and/or the offspring, the hor-
monal milieu of pregnancy is an area of interest for fur-
ther investigation. Longitudinal studies investigating
hormonal patterns from pre-conception through post-
partum should be considered.
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